← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 ArriVent BioPharma AVBP $799M	157	+18	+13%	$1.6B
77	77 BillionToOne Inc BLLN $4.62B	156	+65	+71%	$1.82B
78	78 Fate Therapeutics FATE $232M	156	-2	-1%	$193M
79	79 Verastem VSTM $698M	156	+1	+0.6%	$363M
80	80 Rigel Pharmaceuticals RIGL $875M	155	-4	-3%	$640M
81	81 C4 Therapeutics CCCC $321M	147	+24	+20%	$548M
82	82 Aura Biosciences AURA $640M	146	+20	+16%	$677M
83	83 Coherus Oncology CHRS $162M	146	-12	-8%	$98.5M
84	84 Candel Therapeutics CADL $694M	137	+23	+20%	$519M
85	85 Caribou Biosciences CRBU $49.3M	137	0	0%	$84.8M
86	86 Immunocore IMCR $1.46B	135	-7	-5%	$1.65B
87	87 Nkarta NKTX $145M	135	+9	+7%	$168M
88	88 Keros Therapeutics KROS $219M	132	-19	-13%	$199M
89	89 Perspective Therapeutics CATX $256M	131	-7	-5%	$298M
90	90 Relmada Therapeutics RLMD $346M	126	+23	+22%	$694M
91	91 MacroGenics MGNX $211M	122	+13	+12%	$225M
92	92 Delcath Systems DCTH $511M	119	-2	-2%	$219M
93	93 Protara Therapeutics TARA $147M	119	+5	+4%	$176M
94	94 Zentalis Pharmaceuticals ZNTL $220M	114	+12	+12%	$229M
95	95 ADC Therapeutics ADCT $185M	113	-5	-4%	$86.7M
96	96 Aktis Oncology AKTS $917M	113	+44	+64%	$1.1B
97	97 Immuneering IMRX $221M	111	+16	+17%	$172M
98	98 Immix Biopharma IMMX $706M	109	+32	+42%	$580M
99	99 Corbus Pharmaceuticals CRBP $85.3M	107	-1	-0.9%	$129M
100	100 Cardiff Oncology CRDF $75.7M	104	-13	-11%	$24.2M